|
Market Cap (5-Nov) $355,827,616 (160th) |
Close (30-Jun) $3.18 |
Volume (30-Jun) 1,248,327 |
Shortsold (30-Oct) 16,712,912 (2.30%) (155th) |
|
52w High $1.07 |
52w Low $0.300 |
P/E 29.24 |
EPS -0.56 |
[ARTICLE] Why it’s so hard to make money from blood tests
A news article has been posted about Healius on the AFR. The article was published around , on 3 December 2023 at 1:57pm.
There’s restructuring ahead at the No. 2 pathology provider Healius, which despite its activist ructions, has yielded a 30 per cent return since its 2023 low.
Read ArticleHLS was $3.18 at the close of trade on 30 June 2023
| Recent Articles about ASX:HLS | |
|---|---|
| 29-Jun | Labor threatens pathology giants with price fixing probe over fee hike
afr.com |
| 19-Dec | Ask the analyst: Why have Healius shares struggled so much?
morningstar.com.au |
| 18-Dec | Diagnostic Imaging Radiates Opportunity
fnarena.com |
| 17-Dec | Australian diagnostic company Healius sells Lumus Imaging for $657 million
akm.ru |
| 2-Dec | Healius Limited Announces Director Departure and Shareholdings
markets.businessinsider.com |
| 25-Nov | Healius Director Increases Stake with New Share Acquisition
nasdaq.com |
| 14-Nov | Healius Limited Refocuses Strategy with Leadership Changes
nasdaq.com |
| 27-Sep | Scott Power: Which health ‘underperformer’ just made a big move?
stockhead.com.au |
| 27-Sep | HSF acts for Healius Limited on $965m sale of Lumus Imaging to Affinity Equity Partners
thelawyermag.com |
| 25-Sep | Jarden upgrades Healius Limited (PGZ) to a Hold
markets.businessinsider.com |
| Tracked |
Find all articles about Healius, including others on the AFR, on the media page.
If you were already registered, log in here.